Literature DB >> 11568088

Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH.

M Navarro1, S Pichini, M Farré, J Ortuño, P N Roset, J Segura, R de la Torre.   

Abstract

BACKGROUND: Saliva is an alternative biologic matrix for drugs-of-abuse testing that offers the advantages of noninvasive, rapid, and easy sampling. We studied the excretion profile of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites in both saliva and plasma, as well the effect of the drug on salivary pH.
METHODS: Saliva and plasma samples were obtained from eight healthy MDMA consumers after ingestion of a single 100-mg dose of the drug. Concentrations of MDMA and its main metabolites, 3,4-methylenedioxyamphetamine (MDA) and 4-hydroxy-3-methoxymethamphetamine (HMMA), in saliva and plasma were measured by gas chromatography-mass spectrometry. Apparent pharmacokinetic parameters for MDMA in saliva were estimated, and the saliva-to-plasma ratio at each time interval was calculated and correlated with salivary pH.
RESULTS: MDMA, MDA, and HMMA were detected in saliva. Salivary concentrations of MDMA were 1728.9-6510.6 microg/L and peaked at 1.5 h after drug intake. This was followed by a progressive decrease, with a mean concentration of 126.2 microg/L at 24 h. The saliva-to-plasma ratio was 32.3-1.2, with a peak of 18.1 at 1.5 h after drug administration. Salivary pH seemed to be affected by MDMA administration; pH values decreased by 0.6 units (mean pH values of 6.9 and 6.8 at 1.5 and 4 h after drug administration vs predose pH of 7.4).
CONCLUSIONS: Measurement of MDMA in saliva is a valuable alternative to determination of plasma drug concentrations in both clinical and toxicologic studies. On-site testing is also facilitated by noninvasive and rapid collection of salivary specimens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11568088

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  16 in total

Review 1.  Interpretation of oral fluid tests for drugs of abuse.

Authors:  Edward J Cone; Marilyn A Huestis
Journal:  Ann N Y Acad Sci       Date:  2007-03-01       Impact factor: 5.691

2.  The impact of the new scene drug "crystal meth" on oral health: a case-control study.

Authors:  Niklas Rommel; Nils H Rohleder; Stefan Wagenpfeil; Roland Härtel-Petri; Frederic Jacob; Klaus-Dietrich Wolff; Marco R Kesting
Journal:  Clin Oral Investig       Date:  2015-07-15       Impact factor: 3.573

3.  MDMA and metabolite disposition in expectorated oral fluid after controlled oral MDMA administration.

Authors:  Allan J Barnes; Karl B Scheidweiler; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2011-10       Impact factor: 3.681

4.  3,4-Methylenedioxymethamphetamine administration on postnatal day 11 in rats increases pituitary-adrenal output and reduces striatal and hippocampal serotonin without altering SERT activity.

Authors:  Michael T Williams; Tori L Schaefer; Lisa A Ehrman; Jessica A Able; Gary A Gudelsky; Renu Sah; Charles V Vorhees
Journal:  Brain Res       Date:  2005-03-28       Impact factor: 3.252

5.  Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration.

Authors:  Nathalie A Desrosiers; Allan J Barnes; Rebecca L Hartman; Karl B Scheidweiler; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-03-08       Impact factor: 4.142

6.  3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration.

Authors:  Rebecca L Hartman; Nathalie A Desrosiers; Allan J Barnes; Keming Yun; Karl B Scheidweiler; Erin A Kolbrich-Spargo; David A Gorelick; Robert S Goodwin; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-11-15       Impact factor: 4.142

7.  Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration.

Authors:  Erin A Kolbrich; Robert S Goodwin; David A Gorelick; Robert J Hayes; Elliot A Stein; Marilyn A Huestis
Journal:  J Clin Psychopharmacol       Date:  2008-08       Impact factor: 3.153

8.  Urinary MDMA, MDA, HMMA, and HMA excretion following controlled MDMA administration to humans.

Authors:  Tsadik T Abraham; Allan J Barnes; Ross H Lowe; Erin A Kolbrich Spargo; Garry Milman; Stephane O Pirnay; David A Gorelick; Robert S Goodwin; Marilyn A Huestis
Journal:  J Anal Toxicol       Date:  2009-10       Impact factor: 3.367

9.  Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults.

Authors:  Erin A Kolbrich; Robert S Goodwin; David A Gorelick; Robert J Hayes; Elliot A Stein; Marilyn A Huestis
Journal:  Ther Drug Monit       Date:  2008-06       Impact factor: 3.681

Review 10.  Clinical pharmacokinetics of amfetamine and related substances: monitoring in conventional and non-conventional matrices.

Authors:  Rafael de la Torre; Magí Farré; Mónica Navarro; Roberta Pacifici; Piergiorgio Zuccaro; Simona Pichini
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.